601 Pennsylvania Avenue, N.W.

Suite 900, South Building

Washington, D.C.  20004-2601

Tel: 202-220-3172

Fax: 202-639-8238

www.NRLN.org

 

 

Board of Directors:

A. J. (Jim) Norby

President

 

Bill Kadereit

Vice President

 

John Leasher

Vice President

Secretary/Treasurer

 

Jane Banfield

Joseph R. (Dick) Ciocca

Robert Foresta

JoAnn Alix-Gagain

Chuck Gilbert

 

-------------------------------

Counsel:

Michael Calabrese

Phyllis Borzi

 

Legislative Counsel:

Marta Bascom

 

Media Relations Director:
Ed Beltram

 

Member Organizations:

Aetna Retirees Association

Ameritech/SBC Retirees

AT&T Retirees (ACE)

Boeing/SPEEA Retirees (Engineering Society)

CWA-CUTW Retirees

Daimler-Chrysler Retirees

Association

Detroit Edison Alliance of  Retirees (DEAR)

GM Retirees-Detroit Diesel

IBM Retirees

Johns Manville Retirees

Lucent Retirees Organization

Monsanto/Solutia Retirees

NAPRI (Prudential)

NWB/US WEST/Qwest

Retiree Association

Portland GE-Enron

Southern New England Tell 

Retirees Association, Inc. (SRA)

TelCo Retirees Association

 

March 9, 2007

 

 

The Honorable Thomas R. Carper

United States Senate

513 Senate Office Building

Washington, DC 20510

 

Dear  Senator Carper:

 

On behalf of the some 2 million retirees and workers represented by the National Retiree Legislative Network, I am writing to request that you sign on as a co-sponsor of the Pharmaceutical Market Access and Drug Safety Act of 2007 (S. 242). We believe there should be a bipartisan effort to pass this bill to allow Americans to purchase lower-priced and safe prescription drugs from Canada and other Western industrialized nations.

 

As Senator Byron Dorgan pointed out in the March 7, 2007 hearing before the Senate Commerce Subcommittee on Trade, the same drugs, manufactured in the same factory, routinely sell for nearly two times as much in the U.S. as they do in other countries.  Americans—especially retirees living on fixed incomes—can no longer afford the high prices on drugs that are maintained through the strangle hold that pharmaceutical companies have on our nation’s consumers.

 

Now is the time for the U.S. Senate to take action to provide some relief on the high cost of drugs through legalizing the importation of competitively priced and safe products.  Americans should not have to continue to endure higher drug prices while the drug industry endeavors to water down or side track S. 242.

 

I shall look forward to learning from you that you will become a co-sponsor of S. 242 and actively work for its passage.

 

Sincerely yours,

President, National Retiree Legislative Network